Ankylosing spondylitis: etiology, pathogenesis, and treatments

Wei Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuxia He(Chinese Academy of Medical Sciences & Peking Union Medical College), Kai-Yuan Cheng(Chinese Academy of Medical Sciences & Peking Union Medical College), Linjie Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Di Chen(Rush University Medical Center), Xiao Wang(Johns Hopkins University), Guixing Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xu Cao(Johns Hopkins University), Xisheng Weng(Chinese Academy of Medical Sciences & Peking Union Medical College)
Bone Research
August 5, 2019
Cited by 496Open Access
Full Text

Abstract

Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen (HLA)‑B27 and the interleukin‑23/17 axis. However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies.


Related Papers

No related papers found

Powered by citation graph analysis